Lundbeck fund backs a $50M launch round for SNIPR Biome, a new brand of CRISPR Cas biotech
The early-stage venture arm for the Lundbeck Foundation has launched a biotech startup that has set sail on the vast microbiome sea. The new company — SNIPR Biome — plans to advance its CRISPR Cas tech to prune targeted bacteria. And the biotech has its eye on going into humans in 2021 as it starts to tackle a wide variety of targets that could be influenced by a tailored immune system response.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
